Le Lézard
Classified in: Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

Christopher & Banks Corporation Reports First Quarter Fiscal 2020 Financial Results


Christopher & Banks Corporation (OTC: CBKC), a specialty women's apparel retailer, today reported results for the first quarter ended May 2, 2020.

First Quarter Fiscal 2020 Highlights:

Keri Jones, President and Chief Executive Officer, commented, "Prior to the COVID-19 pandemic, we were both pleased and highly encouraged with the momentum in our business. We had made tremendous progress across our strategic initiatives, which was reflected in our strong comp growth, our operating margin expansion and growing customer file. We had a strong start to fiscal 2020 with nearly 5% comparable sales growth in February. When the pandemic hit, the team was agile and decisive, taking dramatic action to stem cash outflows. In addition, subsequent to the end of the quarter, we secured a $10 million PPP loan under the SBA's alternative size standard. We plan to use these funds for qualified expenses and therefore expect the loan to be forgiven under these usage terms.

Ms. Jones continued, "As of today, we have reopened approximately 90% of our store base open and are pleased to see sales volume building in line with our expectations. Quarter-to-date digital sales are up 50% and we are encouraged to see some of our store-only customers purchasing online for the first time. We will continue to carefully manage expenses and protect cash as we navigate the coming months and position ourselves to regain the momentum that we began to experience as a result of our turnaround strategies. As we emerge from this crisis, we see opportunity to gain further market share as a result of the market disruption given our highly loyal customer base, strong value proposition and expanded omni-channel capabilities."

Results for the First Quarter Ended May 2, 2020

Balance Sheet Highlights and Capital Expenditures

Cash and cash equivalents totaled $0.2 million with $16.8 million in outstanding borrowings and net availability of $4.1 million under the credit facility as of the end of the first quarter. The company also has $5 million drawn on the Term Loan facility, which allows for an aggregate principal amount of up to $10 million. The $10 million PPP loan amount it not reflected in first quarter cash and cash equivalents as it occurred subsequent to the end of the quarter.

Total inventory at the end of the first quarter was $47.4 million at the end of the first quarter of 2020, up 3.7% compared to $45.7 million at the end of the same period last year.

Capital expenditures for the first quarter of 2020 were $0.4 million compared to $0.6 million in last year's first quarter. This primarily reflects investments in support of new stores.

_____________________

*Adjusted EBITDA is a non-GAAP financial measure. The Company defines Adjusted EBITDA as Net income (loss), adjusted for Income tax provision (benefit); Other income; Interest expense, net; Depreciation and Amortization; Stock compensation; Impairment of long-lived assets; and certain discretionary items. Please see "Non-GAAP Measures" below and reconciliations of this non-GAAP measure to the comparable GAAP measure that follows in the table below.

**Adjusted loss per share is a non-GAAP financial measure. The Company defines adjusted loss per share as GAAP loss per share adjusted for certain discretionary items as outlined in the reconciliation of this non-GAAP measure to the comparable GAAP measure that follows in the table below.

COVID-19 Response

The Company took multiple actions in response to the COVID-19 pandemic. These actions included:

Business Update

The Company began to gradually reopen its store base on April 27, 2020 in line with state and local guidelines and in adherence to recommended health and safety measures. As of today, the Company has reopened 90% of its retail store base with sales volume on average building in line with expectations.

In response to the uncertainty from the COVID-19 Coronavirus, the Company will not be providing guidance for fiscal 2020 at this time.

Conference Call Information

The Company will discuss its first quarter fiscal 2020 results in a conference call scheduled for today, June 12, 2020, at 8:30 a.m. Eastern Time. Investors and analysts interested in participating in the call are invited to dial (877) 705-6003 or (201) 493-6725 if calling internationally. Please dial in approximately 10 minutes prior to the start of the call. The conference call will be simultaneously broadcast live over the Internet at http://www.christopherandbanks.com. An online archive of the broadcast will be available within approximately one hour of the completion of the call and will be accessible at http://www.christopherandbanks.com for thirty days. In addition, an audio replay of the call will be available shortly after its conclusion and will be archived until June 19, 2020. This call may be accessed by dialing 1-844-512-2921 and using the passcode 13704470.

Non-GAAP Measures

In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), this press release contains non-GAAP financial measures, Adjusted EBITDA and adjusted loss per share. The presentation of these non-GAAP measures is not in accordance with GAAP, and should not be considered superior to or as a substitute for net income or net loss, or any other measure of performance derived in accordance with GAAP. The Company believes the inclusion of these non-GAAP measures provides useful supplemental information to investors regarding the underlying performance of the Company's business operations, especially when comparing such results to previous periods. These non-GAAP measures are not an alternative for measures of financial performance prepared in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Investors are encouraged to review the reconciliation of the non-GAAP financial measures to its most directly comparable GAAP measure as provided in the tables below.

About Christopher & Banks

Christopher & Banks Corporation is a Minneapolis-based specialty retailer featuring exclusively designed privately branded women's apparel and accessories. As of June 8, 2020, the Company operates 445 stores in 44 states consisting of 309 MPW stores, 77 Outlet stores, 31 Christopher & Banks stores, and 28 stores in its women's plus size clothing division CJ Banks. The Company also operates the www.ChristopherandBanks.com eCommerce website.

Forward-Looking Statements

Certain statements in this press release and in our upcoming earnings conference call may constitute forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect our current views with respect to certain events that could have an effect on our future performance. The forward-looking statements relate to expectations concerning matters that are not historical facts and may use the words "will", "expect", "anticipate", "plan", "intend", "project", "believe", "should", "drive" "in order to" and similar expressions. Except for historical information, matters discussed in this press release or on our earnings conference call may be considered forward-looking statements.

These forward-looking statements are based largely on information currently available to our management and our current expectations, assumptions, plans, estimates, judgments and projections about our business and our industry, and are subject to a number of uncertainties and risks, as well as assumptions that, if they do not fully materialize or prove incorrect, could cause the Company's future performance and financial results to differ materially from those expressed or implied by the forward-looking statements. We cannot guarantee their accuracy or our future performance, and there are a number of known and unknown risks, uncertainties, contingencies, and other factors (many of which are outside our control) that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Accordingly, there is no assurance that our expectations will, in fact, be achieved or that our estimates or assumptions will be correct, and we caution investors and all others not to place undue reliance on such forward-looking statements.

Important factors that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include, but are not limited to, those factors described in Item 1A, "Risk Factors" and in the "Forward-Looking Statements" disclosure in "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" of our latest annual report on Form 10-K and in our subsequent Form 10-Q Reports. All forward-looking statements that are made or attributable to us are expressly qualified in their entirety by this cautionary notice. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that projected results expressed or implied in such statements will not be realized.

 
CHRISTOPHER & BANKS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
 
Thirteen Weeks Ended
May 2, May 4,

2020

2019

Net sales $

40,125

$

83,220

Merchandise, buying and occupancy costs

36,401

57,606

Gross profit

3,724

25,614

Other operating expenses:
Selling, general and administrative

18,523

29,188

Depreciation and amortization

1,906

2,382

Impairment of long-lived assets

264

?

Total other operating expenses

20,693

31,570

Operating loss

(16,969)

(5,956)

Interest expense, net

(273)

(156)

Loss before income taxes

(17,242)

(6,112)

Income tax (benefit) provision

(4)

40

Net loss $

(17,238)

$

(6,152)

 
Basic loss per share:
Net loss $

(0.46)

$

(0.16)

Basic shares outstanding

37,555

37,400

 
Diluted loss per share:
Net loss $

(0.46)

$

(0.16)

Diluted shares outstanding

37,555

37,400

 

CHRISTOPHER & BANKS CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

 

May 2,

May 4,

2020

2019

ASSETS
Current assets:
Cash and cash equivalents $

183

 

$

2,628

 

Accounts receivable

1,619

 

4,018

 

Merchandise inventories

47,390

 

45,704

 

Prepaid expenses and other current assets

3,251

 

4,108

 

Income taxes receivable

374

 

257

 

Total current assets

52,817

 

56,715

 

Non-current assets:
Property, equipment and improvements, net

23,416

 

29,812

 

Operating lease assets

104,735

 

129,521

 

Deferred income taxes

613

 

499

 

Other assets

1,160

 

744

 

Total non-current assets

129,924

 

160,576

 

Total assets $

182,741

 

$

217,291

 

 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $

22,669

 

$

19,421

 

Short-term borrowings

16,797

 

3,000

 

Current portion of long-term debt

167

 

?

 

Current portion of long-term lease liabilities

29,201

 

30,054

 

Accrued salaries, wages and related expenses

2,082

 

3,943

 

Accrued liabilities and other current liabilities

18,380

 

22,764

 

Total current liabilities

89,296

 

79,182

 

 
Non-current liabilities:
Long-term lease liabilities

94,757

 

118,217

 

Long-term debt

4,833

 

?

 

Other non-current liabilities

1,825

 

2,031

 

Total non-current liabilities

101,415

 

120,248

 

 
Stockholders' equity:
Common stock

452

 

463

 

Additional paid-in capital

129,573

 

128,964

 

(Accumulated deficit) retained earnings

(25,120

)

1,307

 

Common stock held in treasury

(112,875

)

(112,873

)

Total stockholders' equity

(7,970

)

17,861

 

Total liabilities and stockholders' equity $

182,741

 

$

217,291

CHRISTOPHER & BANKS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 
Thirteen Weeks Ended
May 2, May 4,

2020

2019

Cash flows from operating activities:
Net loss $

(17,238)

$

(6,152)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,906

2,382

Impairment of long-lived assets

264

?

Amortization of financing costs

51

5

Lease expense

5,563

5,366

Stock-based compensation expense

162

253

Changes in operating assets and liabilities:
Accounts receivable

1,356

(1,251)

Merchandise inventories

(5,692)

(4,666)

Prepaid expenses and other assets

1,098

(771)

Income taxes receivable

(84)

11

Accounts payable

(1,121)

1,650

Accrued liabilities

(8,278)

(1,100)

Lease liabilities

(2,020)

(5,589)

Other liabilities

9

(77)

Net cash used in operating activities

(24,024)

(9,939)

 
Cash flows from investing activities:
Purchases of property, equipment and improvements

(395)

(587)

Net cash used in investing activities

(395)

(587)

 
Cash flows from financing activities:
Shares redeemed for payroll taxes

(2)

(3)

Proceeds from bank credit facility

16,797

12,650

Payments on bank credit facility

?

(9,650)

Payments for debt issuance costs

(391)

?

Proceeds from long-term borrowings

5,000

?

Acquisition of common stock held in treasury, at cost

?

(82)

Net cash provided by financing activities

21,404

2,915

 
Net decrease in cash and cash equivalents

(3,015)

(7,611)

Cash and cash equivalents at beginning of period

3,198

10,239

Cash and cash equivalents at end of period $

183

$

2,628

 
Supplemental cash flow information:
Interest paid $

273

$

156

Income taxes paid $

?

$

(7)

Accrued purchases of equipment and improvements $

184

$

122

 
CHRISTOPHER & BANKS CORPORATION AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA
(in thousands)
(unaudited)
 
The following table reconciles from Net loss in accordance with generally accepted accounting
principles (GAAP) to Adjusted EBITDA, a non-GAAP measure, for the thirteen weeks ended May 2,
2020 and May 4, 2019:
 
Thirteen Weeks Ended
May 2, May 4,

2020

2019

Net loss on a GAAP basis $

(17,238)

$

(6,152)

Income tax (benefit) provision

(4)

40

Interest expense, net

(273)

(156)

Depreciation & amortization

1,906

2,382

Impairment of long-lived assets

264

?

Executive severance

?

396

Stock based compensation

162

253

Adjusted EBITDA $

(14,637)

$

(2,925)

 
 
 
CHRISTOPHER & BANKS CORPORATION AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION OF LOSS PER SHARE
(in thousands, except per share data)
(unaudited)
 
The following table reconciles Net loss per share in accordance with GAAP to Adjusted net loss per
share, on a non-GAAP basis, for the thirteen weeks ended May 2, 2020 and May 4, 2019:
 
 
Thirteen Weeks Ended
May 2, May 4,

2020

2019

Pretax Net of tax Per share amounts Pretax Net of tax Per share amounts
GAAP net loss per share $

(0.46)

$

(0.16)

Adjustments
Impairment of long-lived assets

264

264

0.01

?

?

0.00

Executive Severance

?

?

0.00

396

396

0.01

Stock based compensation

162

162

0.00

253

251

0.01

Adjusted loss per share $

(0.45)

$

(0.14)

 


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: